133 related articles for article (PubMed ID: 32891685)
1. Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.
Tong M; Fang X; Yang J; Wu P; Guo Y; Sun J
Immunol Lett; 2020 Nov; 227():96-101. PubMed ID: 32891685
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity.
Hirahara S; Katsumata Y; Kawasumi H; Kawaguchi Y; Harigai M
Lupus; 2020 Jun; 29(7):686-696. PubMed ID: 32264742
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
[TBL] [Abstract][Full Text] [Related]
4. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.
Liu MF; Weng CT; Weng MY
J Biomed Biotechnol; 2009; 2009():406136. PubMed ID: 19759858
[TBL] [Abstract][Full Text] [Related]
5. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
6. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T; Yoshizaki A; Ebata S; Nakamura K; Saigusa R; Miura S; Yamashita T; Hirabayashi M; Ichimura Y; Taniguchi T; Asano Y; Shimizu H; Kazoe Y; Mawatari K; Kitamori T; Sato S
Arthritis Rheumatol; 2017 Sep; 69(9):1879-1890. PubMed ID: 28556548
[TBL] [Abstract][Full Text] [Related]
7. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB-
Moriyama R; Katsumata Y; Okamoto Y; Harigai M
Lupus; 2024 Jul; 33(8):816-827. PubMed ID: 38622764
[TBL] [Abstract][Full Text] [Related]
9. The PD-1/PD-Ls pathway and autoimmune diseases.
Dai S; Jia R; Zhang X; Fang Q; Huang L
Cell Immunol; 2014 Jul; 290(1):72-9. PubMed ID: 24908630
[TBL] [Abstract][Full Text] [Related]
10. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of bovine programmed death-ligand 2.
Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
[TBL] [Abstract][Full Text] [Related]
12. PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus.
Luo Q; Huang Z; Ye J; Deng Y; Fang L; Li X; Guo Y; Jiang H; Ju B; Huang Q; Li J
Arthritis Res Ther; 2016 Feb; 18():47. PubMed ID: 26867643
[TBL] [Abstract][Full Text] [Related]
13. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
14. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated PD-L2 is correlated with disease activity and inflammation in rheumatoid arthritis.
Xiong J; Yang J; Sun Y; Chen Y; Guo Y; Liu C; Sun J
Immunogenetics; 2023 Oct; 75(5):425-431. PubMed ID: 37405419
[TBL] [Abstract][Full Text] [Related]
17. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.
Bertsias GK; Nakou M; Choulaki C; Raptopoulou A; Papadimitraki E; Goulielmos G; Kritikos H; Sidiropoulos P; Tzardi M; Kardassis D; Mamalaki C; Boumpas DT
Arthritis Rheum; 2009 Jan; 60(1):207-18. PubMed ID: 19116915
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
19. PD-1 immunobiology in systemic lupus erythematosus.
Curran CS; Gupta S; Sanz I; Sharon E
J Autoimmun; 2019 Feb; 97():1-9. PubMed ID: 30396745
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
